Global Ophthalmic Reach Sentiss operates across India, USA, Europe, Dubai, Russia and Central Asia with a strong position as the largest ophthalmic company in Russia, indicating substantial regional demand and prime entry points for eye care generics and innovative ophthalmic products.

Expansion via Acquisitions The acquisition of Akorn AG in Switzerland adds a US FDA approved sterile manufacturing facility for ophthalmic drops and ointments, creating new sales avenues, faster time-to-market, and enhanced credentials for contract manufacturing opportunities.

CSR and Workplace Advantage Consistent CSR award recognition and multiple years of Great Place to Work certification can be leveraged in sales discussions to reassure customers and partners about reliability, governance, and supplier stability.

Full-Spectrum Ophthalmic Capabilities With a state-of-the-art R&D center, dual sterile manufacturing sites, and end-to-end operations capabilities, Sentiss is well positioned to offer custom formulations, in-licensing/out-licensing deals, and contract manufacturing to global buyers seeking eye care solutions.

Financial Scale and Partnerships Revenue in the billion-dollar range combined with extensive partnerships suggests capacity for large-volume supply agreements, as well as collaboration on innovative ophthalmic products to capture growing demand in eye care markets.